Cargando…
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232594/ https://www.ncbi.nlm.nih.gov/pubmed/35750664 http://dx.doi.org/10.1038/s41408-022-00691-9 |
| _version_ | 1784735621297733632 |
|---|---|
| author | Ghorab, Ahmad Al-Kali, Aref Elliot, Michelle Gangat, Naseema Alkhateeb, Hasan Shah, Mithun Liu, Yuanhang Yi, Cecilia Arana Murthy, Hemant Kharfan-Dabaja, Mohamed Tefferi, Ayalew Patnaik, Mrinal Litzow, Mark Badar, Talha |
| author_facet | Ghorab, Ahmad Al-Kali, Aref Elliot, Michelle Gangat, Naseema Alkhateeb, Hasan Shah, Mithun Liu, Yuanhang Yi, Cecilia Arana Murthy, Hemant Kharfan-Dabaja, Mohamed Tefferi, Ayalew Patnaik, Mrinal Litzow, Mark Badar, Talha |
| author_sort | Ghorab, Ahmad |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9232594 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92325942022-06-26 Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs Ghorab, Ahmad Al-Kali, Aref Elliot, Michelle Gangat, Naseema Alkhateeb, Hasan Shah, Mithun Liu, Yuanhang Yi, Cecilia Arana Murthy, Hemant Kharfan-Dabaja, Mohamed Tefferi, Ayalew Patnaik, Mrinal Litzow, Mark Badar, Talha Blood Cancer J Correspondence Nature Publishing Group UK 2022-06-24 /pmc/articles/PMC9232594/ /pubmed/35750664 http://dx.doi.org/10.1038/s41408-022-00691-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Ghorab, Ahmad Al-Kali, Aref Elliot, Michelle Gangat, Naseema Alkhateeb, Hasan Shah, Mithun Liu, Yuanhang Yi, Cecilia Arana Murthy, Hemant Kharfan-Dabaja, Mohamed Tefferi, Ayalew Patnaik, Mrinal Litzow, Mark Badar, Talha Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs |
| title | Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs |
| title_full | Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs |
| title_fullStr | Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs |
| title_full_unstemmed | Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs |
| title_short | Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs |
| title_sort | clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232594/ https://www.ncbi.nlm.nih.gov/pubmed/35750664 http://dx.doi.org/10.1038/s41408-022-00691-9 |
| work_keys_str_mv | AT ghorabahmad clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT alkaliaref clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT elliotmichelle clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT gangatnaseema clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT alkhateebhasan clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT shahmithun clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT liuyuanhang clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT yiceciliaarana clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT murthyhemant clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT kharfandabajamohamed clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT tefferiayalew clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT patnaikmrinal clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT litzowmark clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds AT badartalha clinicaloutcomeofmyelodysplasticsyndromeprogressingonhypomethylatingagentswithevolvingfrontlinetherapiescontinuedchallengesandunmetneeds |